DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ljs26p/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Tekmira Pharmaceuticals Corp.
- Actavis plc
- Isis Pharmaceuticals, Inc.
- Novartis AG
- Astellas Pharma Inc.
- Amarin Corporation plc
- Alnylam Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals, Inc.
- Cardax Pharmaceuticals, Inc.
- Essentialis, Inc.
- Epax AS
- Pharmena SA
- FORMAC Pharmaceuticals N.V.
- Omthera Pharmaceuticals, Inc.
- Poxel SA
- Acasti Pharma Inc.
Drug Profiles
- icosapent ethyl
- omega-3-carboxylic acids
- diazoxide CR
- AKR-963
- TRIA-662
- ISIS-APOCIIIRx
- NKPL-66
- pradigastat sodium
- CAT-2003
- fenofibrate
- bezafibrate ER
- CDX-085
- CAT-2000 Series
- AS-1708727
- MAT-9001
- Drug For Hypertriglyceridemia
- ALN-ANG
- Small Molecule Farnesoid X Receptor Agonist for Gastrointestinal, Metabolic and Cardiovascular Diseases
- Peptides for Dyslipidemic and Vascular Disorders
For more information visit http://www.researchandmarkets.com/research/ljs26p/high
